Overview

Leerink’s weekly prescription‑drug analysis for the United States covering the period ending 5 June 2026 shows a rebound in overall market demand after the Memorial Day weekend.

Market‑wide performance

The total U.S. drug market posted a week‑over‑week increase of 10 percent, reversing the 8 percent decline recorded in the preceding week.

Key product trends

  • Tirzepatide (branded Mounjaro and Zepbound) recorded year‑over‑year prescription growth of 46 percent for the one‑week window, 51 percent for the four‑week window and 57 percent for the twelve‑week window.
  • Semaglutide (branded Ozempic and Wegovy) showed year‑over‑year growth of 22 percent, 21 percent and 18 percent for the one‑, four‑ and twelve‑week periods respectively.
  • The combined Wegovy franchise, including both injectable and oral formulations, rose 10 percent week‑over‑week, while Zepbound increased 9 percent week‑over‑week.

Launch performance

  • Foundayo generated roughly 20,000 prescriptions in its ninth week of launch, a 17 percent week‑over‑week rise, representing less than 25 percent of the approximately 81,000 prescriptions written for oral Wegovy in its ninth week.
  • Oral Wegovy reached about 159,000 prescriptions in its 22nd week, up 19 percent from roughly 134,000 prescriptions in week 21. Leerink notes that IQVIA’s oral Wegovy data are understated because they omit certain direct‑to‑consumer channels.

AbbVie product growth

  • AbbVie’s Skyrizi posted year‑over‑year growth of 26 percent for both the one‑week and four‑week periods and 35 percent for the fifty‑two‑week period.
  • AbbVie’s Rinvoq showed year‑over‑year growth of 19 percent (one‑week), 25 percent (four‑week) and 29 percent (fifty‑two‑week).

Johnson & Johnson product growth

  • Johnson & Johnson’s Tremfya recorded year‑over‑year growth of 68 percent for one week, 71 percent for four weeks and 52 percent for fifty‑two weeks, supported by recent inflammatory‑bowel‑disease launches with full subcutaneous dosing schedules.

Vertex and Bristol Myers updates

  • Vertex Pharmaceuticals’ acute‑pain drug Journavx generated approximately 22,000 prescriptions in its 67th week, a 20 percent increase from the prior week’s roughly 18,000 prescriptions.
  • Bristol Myers Squibb’s Cobenfy prescriptions rose 18 percent week‑over‑week after a 13 percent decline in the previous week.

Methodology note

The analysis was produced with AI assistance and reviewed by an editor; IQVIA data for oral Wegovy are acknowledged as incomplete.